EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Allurion Technologies's Enterprise Value is $30.30 Mil.
Allurion Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-22.70 Mil. Therefore, Allurion Technologies's EV-to-FCF for today is -1.34.
The historical rank and industry rank for Allurion Technologies's EV-to-FCF or its related term are showing as below:
ALURD'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.54 Med: -1.14 Max: -0.54
Current: -1.34
During the past 5 years, the highest EV-to-FCF of Allurion Technologies was -0.54. The lowest was -8.54. And the median was -1.14.
ALURD's EV-to-FCF is ranked worse than 100% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.66
vs ALURD: -1.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allurion Technologies's PE Ratio (TTM) for today is calculated as:
Allurion Technologies's share price for today is $5.91.
Allurion Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-54.750.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Allurion Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's EV-to-FCF falls into.
Allurion Technologies's current Enterprise Value is $30.30 Mil.
Allurion Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allurion Technologies (ALURD) has a EV-to-FCF of -1.34 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Allurion Technologies and its competitors. According to the industry distribution chart, Allurion Technologies ranks #999999 out of 418 companies in the Medical Devices & Instruments industry.
Is Allurion Technologies' EV-to-FCF too high?
Allurion Technologies' current EV-to-FCF is -1.34. Based on the distribution chart, Allurion Technologies ranks #999999 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Allurion Technologies has a GF Score™ of 16/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Allurion Technologies' EV-to-FCF compare to ALRTF and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Allurion Technologies ranks #999999 out of 418 companies for EV-to-FCF. This places Allurion Technologies in the lower half of its industry. The industry median EV-to-FCF is 22.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.66, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Allurion Technologies and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allurion Technologies's current EV-to-FCF is -1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allurion Technologies stock overvalued right now?
Based on GuruFocus' analysis, Allurion Technologies (ALURD) is currently considered Possible Value Trap. The stock's GF Value™ is $10.66, compared to a current price of $5.91 — trading 44.6% below its estimated fair value. The current EV-to-FCF is -1.34. Allurion Technologies' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Allurion Technologies (ALURD), the current EV-to-FCF is -1.34 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allurion Technologies (ALURD) Overvalued in 2026?
Based on GuruFocus' analysis, Allurion Technologies stock appears to be undervalued.
The current stock price of $5.91 is trading 44.6% below its estimated GF Value™ of $10.66.
GuruFocus considers Allurion Technologies to be Possible Value Trap.
Key valuation signals for ALURD:
EV-to-FCF: -1.34
GF Value™: $10.66 vs. price of $5.91 (44.6% below fair value)
No single metric tells the full story. See the ALURD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
16GF Score
Get the complete analysis for ALURD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALURD has been successfully added to your 
